What Rigel Pharmaceuticals, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 3 |
| Total trades | 8 | 48 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 4,600 | 295,503 |
| Disposed | 5,103 | 141,978 |
| Net activity | −503 | +153,525 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Schorno Dean L | EVP & Chief Financial Officer | Sep 02 | Exercise / conversion · M | +1,286 | $24.20 | +$31.1K | 82,962 |
| Schorno Dean L | EVP & Chief Financial Officer | Sep 02 | Exercise / conversion · M | +2,000 | $24.20 | +$48.4K | 81,676 |
| Schorno Dean L | EVP & Chief Financial Officer | Sep 02 | Exercise / conversion · M | +620 | $18.70 | +$11.6K | 79,676 |
| Schorno Dean L | EVP & Chief Financial Officer | Sep 02 | Exercise / conversion · M | +694 | $12.70 | +$8.81K | 79,056 |
| Schorno Dean L | EVP & Chief Financial Officer | Sep 01 | Withheld — tax / exercise cost · F | −928 | $47.50 | −$44.1K | 78,362 |
| Santos David A | EVP, Chief Commercial Officer | Sep 01 | Withheld — tax / exercise cost · F | −874 | $47.50 | −$41.5K | 61,622 |
| Rodriguez Raul R | CEO, President | Sep 01 | Withheld — tax / exercise cost · F | −2,424 | $47.50 | −$115K | 273,362 |
| Furey Raymond J. | EVP, GC, CCO & Corp Sec | Sep 01 | Withheld — tax / exercise cost · F | −877 | $47.50 | −$41.7K | 50,559 |
| Hannah Alison L. | EVP, Chief Medical Officer | Jul 08 | Grant / award · A | +24,400 | — | — | 35,025 |
| Ali-Jackson Kamil | Director | Jun 22 | Open-market sale · S | −2,500 | $35.00 | −$87.5K | 10,125 |
| Furey Raymond J. | EVP, GC, CCO & Corp Sec | Jun 01 | Withheld — tax / exercise cost · F | −877 | $29.86 | −$26.2K | 50,936 |
| Rojkjaer Lisa | EVP, Chief Medical Officer | Jun 01 | Withheld — tax / exercise cost · F | −850 | $29.86 | −$25.4K | 34,003 |
| Rodriguez Raul R | CEO, President | Jun 01 | Withheld — tax / exercise cost · F | −2,424 | $29.86 | −$72.4K | 279,593 |
| Santos David A | EVP, Chief Commercial Officer | Jun 01 | Withheld — tax / exercise cost · F | −874 | $29.86 | −$26.1K | 61,996 |
| Schorno Dean L | EVP & Chief Financial Officer | Jun 01 | Withheld — tax / exercise cost · F | −928 | $29.86 | −$27.7K | 78,790 |
| Schorno Dean L | EVP & Chief Financial Officer | Jun 01 | Exercise / conversion · M | +2,181 | $12.70 | +$27.7K | 79,718 |
| Schorno Dean L | EVP & Chief Financial Officer | Jun 01 | Exercise / conversion · M | +1,200 | $18.70 | +$22.4K | 77,537 |
| Ali-Jackson Kamil | Director | May 26 | Open-market sale · S | −2,500 | $29.17 | −$72.9K | 12,625 |
| Lapointe Gregg Anthony | Director | May 15 | Grant / award · A | +5,750 | — | — | 18,250 |
| Ali-Jackson Kamil | Director | May 15 | Grant / award · A | +5,750 | — | — | 15,125 |
Loading...
